Toshihiko Doi, MD, PhD, on Esophageal Carcinoma: Study Results From KEYNOTE-028
2016 Gastrointestinal Cancers Symposium
Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).
Richard S. Finn, MD
Richard S. Finn, MD, of the University of California Los Angeles Medical Center, summarizes a session on treatments for advanced hepatocellular carcinoma (Abstract 192).
James L. Abbruzzese, MD
James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.
Simron Singh, MD
Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).
Heinz-Josef Lenz, MD
Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses in German the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patients with metastatic colorectal cancer (Abstract 493).
Daniel G. Haller, MD
Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.